News und Analysen
What's Behind Pacific Biosciences of California's Stock Rally Today?
Shares of Pacific Biosciences of California (NASDAQ: PACB) are on the rise again. This is the third trading session in a row that the stock has marched upwards since announcing record revenues and a
bluebird bio Pauses During 2017 Data Blitz
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and
Why Minerva Neurosciences Inc. Fell 31.1% in July
Shares of Minerva Neurosciences (NASDAQ: NERV), a clinical-stage biotech focused on diseases of the central nervous system, fell more than 31% in July, according to data from S&P Global Market
Why Flexion Therapeutics Shares Shot 12.8% Higher in July
After the company hosted an investor's day on July 10, shares in Flexion Therapeutics (NASDAQ: FLXN) jumped 12.8% last month, according to S&P Global Market Intelligence.Flexion Therapeutics doesn't
Here's Why Myokardia Inc. Stock Shot Up Today
Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
Is Illumina Stock a Buy at Nearly 40 Times Earnings? 1 Analyst Thinks So
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one
Why Horizon Pharma plc Stock Is Rising Today
Horizon Pharma (NASDAQ: HZNP), a specialty pharma company, saw its shares rise by as much as 21% in pre-market trading today. The drugmaker's stock is rising in response to a better-than-expected
These 3 Biotechs Just Crushed Analyst Expectations
Earnings season is under way, and biotech business appears to be booming. But it takes more than just a good quarter to know if a biotech is poised for sustainable, long-term growth. With many
Why You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors. It's easy to see why; if a company dumps a bucket of new stock on the market, existing
Here's Why Mazor Robotics Ltd. Gained 20% in July
Shares of robot-assisted surgery start-up Mazor Robotics Ltd. (NASDAQ: MZOR) gained 20% in July, according to data from S&P Global Market Intelligence. The market boosted the stock in response to news
Here's Why Mazor Robotics Ltd. Gained 20% in July
Shares of robot-assisted surgery start-up Mazor Robotics Ltd. (NASDAQ: MZOR) gained 20% in July, according to data from S&P Global Market Intelligence. The market boosted the stock in response to news
Here's Why Mazor Robotics Ltd. Gained 20% in July
Shares of robot-assisted surgery start-up Mazor Robotics Ltd. (NASDAQ: MZOR) gained 20% in July, according to data from S&P Global Market Intelligence. The market boosted the stock in response to news
Better Buy: Intuitive Surgical, Inc. vs. Medtronic plc
Investing in medical device companies can be ridiculously profitable.Since their respective IPOs, shares of Intuitive Surgical (NASDAQ: ISRG) -- maker of the daVinci robotic surgical system -- and
Dividendeneinnahmen im Juli 2017
Nachfolgend veröffentliche ich die Liste meiner Dividendeneinnahmen nach Steuerabzug im Juli 2017:Wertpapiername Dividende ALTRIA GRP INC. 39,52 € BK NOVA SCOTIA 30,47 € COCA-COLA CO. ....
Dividendeneinnahmen im Juli 2017
Nachfolgend veröffentliche ich die Liste meiner Dividendeneinnahmen nach Steuerabzug im Juli 2017:Wertpapiername Dividende ALTRIA GRP INC. 39,52 € BK NOVA SCOTIA 30,47 € COCA-COLA CO. ....
3 Things You Need to Know About Marijuana Stock Cara Therapeutics
Cara Therapeutics (NASDAQ: CARA) announced its second-quarter financial results after the market closed on Thursday. The next day, Cara stock soared. But it wasn't because of the financial numbers
The Top Stock You Should Consider for Your IRA
If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA, you won't have to pay
10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year
If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation
Why GW Pharmaceuticals Could Be a Gold Mine for Growth Investors
You've probably heard of the great California gold rush of the mid-19th century. Today, many are flocking to what has been called the "green rush" -- a major wave of money flowing into the marijuana
Insulet Delivers 26% Revenue Growth and Raises 2017 Guidance; Stock Pumps Up 7%
Insulet (NASDAQ: PODD) reported second-quarter 2017 earnings after the market closed on Thursday. The drug-delivery company, which is a leader in tubeless insulin pump technology with its Omnipod
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE: